Neuren PharmaceuticalsNURPF +2.48%49 Operating Margin % is 30.57% as of Dec. 2025, which is 22% below its 10-year median of 39.07. GuruFocus rates NURPF with a GF Score™ of 49/100 and a GF Value™ of $4.40 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Neuren Pharmaceuticals ranks better than 94.5% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Neuren Pharmaceuticals Operating Margin % Related Terms
Neuren Pharmaceuticals Operating Margin % Historical Data
* Premium members only.
The historical data trend for Neuren Pharmaceuticals's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NURPF vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Neuren Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Neuren Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (NURPF) has a Operating Margin % of 30.57% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Neuren Pharmaceuticals and its competitors. This is 22% below median its historical median of 39.07. According to the industry distribution chart, Neuren Pharmaceuticals ranks #52 out of 945 companies in the Biotechnology industry, placing it in the top 5.5%.
Is Neuren Pharmaceuticals' Operating Margin % too high?
Neuren Pharmaceuticals' current Operating Margin % of 30.57% is 22% below median its 10-year median of 39.07. Based on the distribution chart, Neuren Pharmaceuticals ranks #52 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #52 out of 945 companies for Operating Margin %. This places Neuren Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Operating Margin % is 30.57%, which is 22% below median its own 10-year median of 39.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (NURPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.40, compared to a current price of $8.69 — trading 97.5% above its estimated fair value. The current Operating Margin % is 30.57%, which is 22% below median its 10-year median of 39.07. Neuren Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Neuren Pharmaceuticals (NURPF), the current Operating Margin % is 30.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (NURPF) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of $8.69 is trading 97.5% above its estimated GF Value™ of $4.40.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NURPF:
Operating Margin %: 30.57% (22% below median its 10-year median of 39.07)
GF Value™: $4.40 vs. price of $8.69 (97.5% above fair value)
No single metric tells the full story. See the NURPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
49GF Score
Get the complete analysis for NURPF
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NURPF has been successfully added to your 
